Robert Weinstein

Robert Weinstein, listed as finance chief, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in XWELL, Inc., TAO Synergies Inc. and PharmaCyte Biotech, Inc. In total, 13 filings cover trades dated from 13 July 2021 to 27 February 2026.

In open-market terms, that means 2 purchases worth €12k on one side and 3 sales worth €151k on the other. Sales outweigh purchases by €139k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 8 share grants.

Most recently, on 2 March 2026, the filings show a share grant in XWELL, Inc. The latest purchase dates back some time: it was published 1,236 days ago, on 31 May 2023. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.